- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05513677
Characterisation of Biofilm Growth on Coated vs. Uncoated Urinary Catheter Surfaces in Normal Clinical Use (PRO30CSP)
Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised)
Selection follows documented hospital protocols for routine catheterisation
Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised)
- 20 who receive the M4D coated catheter.
- 10 who receive the standard uncoated catheters used in routine patient care.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Evaluated Patients: 5 patients (Convenience sample: non-blinded, non-randomised)
Selection follows documented hospital protocols for routine catheterisation
Measured Patients: 30 patients (Convenience sample: non-blinded and non-randomised)
- 20 who receive the M4D coated catheter.
- 10 who receive the standard uncoated catheters used in routine patient care.
1) Evaluation (5 patients, coated catheter)
A convenience sample of patients will be selected to receive the Camstent coated catheter for their routine care. These enrolments are drawn from among those recommended for routine catheterisation, for up to 28 days and in accordance to existing hospital protocols. There is no change to the routine protocols for insertion, maintenance, withdrawal, or documentation of the patient's catheterisation. Following use, the catheter is discarded according to the hospital's procedures.
Staff questionnaires will be completed to capture general use information. These will document the opinions of the nurse inserting and withdrawing the catheter, and may include questions for the patient, to record their experience. There will be no collection of patient information, and no analysis of the discarded catheter.
2) Measurement (10 patients receiving uncoated catheters, 20 patients receiving coated catheters)
The data collection will include 10 patients who have received the standard hospital issued uncoated catheter and 20 patients who have received the Camstent coated catheter. There will be no randomisation and no blinding.
The first 10 patients needing routine urinary catheterisation to drain their bladder for up to 28 days whilst in hospital will receive the routine hospital issued catheter and will looked after by hospital and staff as standard practice.
The next 20 patients needing routine urinary catheterisation to drain their bladder whilst in hospital will receive a coated catheter. There will be no change to the intended use of the catheter for patients where it is deemed medically necessary to drain urine from the urinary bladder via the urethra using the catheter device for up to 28 days. There will be no change to any patient care or catheterisation procedures.
All 30 catheters will be sent to a laboratory for surface examination rather than immediately disposed of as medical waste. Harvested catheters will be bagged in an airtight plastic bag and tagged with a record identifier. A record identifier will be used to establish catheter traceability and duration, and will not compromise patient anonymity. The catheter will be kept refrigerated and transported to the analysis laboratory at Nottingham University within two days.
At the Nottingham Laboratory, the catheters will be subjected to qualitative and quantitative analysis to determine the percentage of biofilm coverage on the surface. This will initially be achieved using staining followed by microscopic visual examination of the catheter surface, and images taken of any surface encrustation.
For Fluorescence Microscopy, the procedure will be:
- Cut the catheter into segments then wash three times in ~15 ml of PBS with gentle agitation.
- Transfer the washed catheter segments into the wells of a sterile 24 well plate and stain with SYTO17 Red Fluorescent Nucleic Acid Stain.
- Segments will be imaged using a laser scanning confocal microscope using a 10 X objective lens over a 1024 μm x 1024 μm area.
- A z-section will be imaged (each section is 4μm apart with 36 images taken over 140μm) such that the entire curved surface is imaged. The coverage data will then be taken from a maximum intensity z-projection.
- Data analysis will be carried out in ImageJ using the maximum intensity z-projection images.
- Images will be converted to 8-bit greyscale images, a threshold applied to select the data correctly and the biofilm coverage measured.
- The percentage of coverage for each sample will be computed as (Light) / (Light + Dark) * 100%.
Aggregate descriptive statistics will be calculated, and biofilm coverage will be plotted against the duration of catheterisation as a scattergram. The study is not powered to permit statistical analysis.
Prior laboratory experiments predict that the difference in biofilm coverage could exceed 80%. If larger differences are seen in harvested catheters, then a Total Cell Count assay, in which the biofilm is sonicated free of the surface and then assessed through serial dilution, may be substituted for Fluorescence Microscopy.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Middlesbrough, Storbritannien, TS4 3BW
- The James Cook University Hospital,
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Exclusion Criteria:
• Patients under age 18.
- Patients that have or recently (within 3 weeks) had a urinary catheter, or those with signs of current urinary tract infection.
- Patients who they have had previous radiation therapy in lower pelvis.
- Patients who are cognitively impaired, or are unwilling to give consent
- Patients with a potentially immunocompromised condition
- Patients that require further antibiotics after initial dose, or those that are administered antibiotics following an infection whilst the trial urinary catheter is in situ
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Standard of Care
|
Standard of Care
|
Experimentell: M4D coated catheter
Experimental
|
Coated catheter
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
The primary outcome is the percentage of catheter surface colonised by biofilm, calculated as (light / (light + dark) x 100% in measurement of stained samples using fluorescence microscopy.
Tidsram: 30 days
|
The primary outcome is the percentage of catheter surface colonised by biofilm, calculated as (light / (light + dark) x 100% in measurement of stained samples using fluorescence microscopy.
|
30 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Secondary outcomes will be logging of events, including catheter blockage or presumed CAUTI.
Tidsram: 30days
|
Secondary outcomes will be logging of events, including catheter blockage or presumed CAUTI.
|
30days
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PRO30CSP
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Urinvägsinfektion
-
Neuspera Medical, Inc.Aktiv, inte rekryterandeUrinary Urgency InkontinensFörenta staterna, Nederländerna, Belgien
-
Oregon Health and Science UniversityAvslutadUrinary Urgency InkontinensFörenta staterna
-
Federal University of Rio Grande do SulRekryteringTandimplantat misslyckades | Sinus TractBrasilien
-
Majmaah UniversityHar inte rekryterat ännuSinus Tract | Singelbesök | Flera besök | Enkel kon obturationsteknik | Biokeramisk tätning
-
Maastricht University Medical CenterWingate Institute of NeurogastroenterologyRekryteringfMRI | Transkutan vagus nervstimulering (tVNS) | Nucleus of the Solitary Tract (NTS)Nederländerna, Storbritannien
-
TC Erciyes UniversityAvslutad
-
International Centre for Diarrhoeal Disease Research...Karolinska Institutet; Swedish International Development Cooperation Agency...Avslutad
-
Institut PasteurRekrytering
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, inte rekryterandeSmärta | Malign neoplasm | Urinary Urgency | Kramp i urinblåsanFörenta staterna
-
Duke UniversityAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Förenta staterna
Kliniska prövningar på Standard of Care
-
Johns Hopkins UniversityRekryteringKompartmentsyndrom i ben | Extrakorporeal membransyresättningskomplikation | Extremitetsischemi, kritisk | ExtremitetsischemiFörenta staterna
-
Rhizen Pharmaceuticals SAIncozen Therapeutics Pvt LtdAvslutad
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) och andra samarbetspartnersAvslutadOproportionerlig form | Utökade fettkuddarFörenta staterna
-
Beth Israel Deaconess Medical CenterAvslutad
-
The Methodist Hospital Research InstituteOkänd
-
Precise Dx, Inc.The Cleveland ClinicHar inte rekryterat ännu
-
Cerus CorporationAvslutadTransfusionsrelaterad akut lungskadaFörenta staterna
-
University of Alabama at BirminghamIndragenFysisk aktivitetFörenta staterna
-
Janssen Research & Development, LLCRekryteringÄrftliga näthinnesjukdomarFörenta staterna, Korea, Republiken av, Kanada, Spanien, Danmark, Tyskland, Frankrike, Italien, Israel, Österrike, Storbritannien